Bleomicina: un modelo de fibrosis pulmonar

bleomycin is a glycopeptide used for cancer treatment, but the therapeutic potencial of this drug is limited by its lung toxicity. the cytotoxic effect of bleomycin is dose-dependent and involves pneumonitis that proceeds to lung fibrosis (lf). alveolar epithelial cells are the main target of bleomycin induced injury. alveolar epithelial cell death by apoptosis is considered as a key event in the initiation and progression of lf, that is characterized by excessive deposition of extracellular matrix, mainly fibrilar collagens in the lung parenchyma. bleomycin has been used as the main fibrogenic agent in animal models in lf basic research; in recent years, a bleomycin model developed in transgenic mice has been used to elucidate the in vivo role of a great number of biomolecules involved in lf.